-DOCSTART- -X- O
We -X- _ O
have -X- _ O
previously -X- _ O
shown -X- _ O
that -X- _ O
the -X- _ O
infection -X- _ O
of -X- _ O
cell -X- _ O
cultures -X- _ O
with -X- _ O
the -X- _ O
arenaviruses -X- _ B-Patient
Junín -X- _ I-Patient
( -X- _ I-Patient
JUNV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
Tacaribe -X- _ I-Patient
( -X- _ I-Patient
TCRV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
and -X- _ O
Pichindé -X- _ O
promotes -X- _ O
the -X- _ O
phosphorylation -X- _ O
of -X- _ O
mitogen-activated -X- _ O
protein -X- _ O
kinases -X- _ O
( -X- _ O
MAPKs -X- _ O
) -X- _ O
extracellular -X- _ O
signal-regulated -X- _ O
kinases -X- _ O
1 -X- _ O
and -X- _ O
2 -X- _ O
( -X- _ O
ERK1 -X- _ O
/ -X- _ O
2 -X- _ O
) -X- _ O
and -X- _ O
that -X- _ O
this -X- _ O
activation -X- _ O
is -X- _ O
required -X- _ O
for -X- _ O
the -X- _ O
achievement -X- _ O
of -X- _ O
a -X- _ O
productive -X- _ O
infection. -X- _ O
Here -X- _ O
we -X- _ O
examined -X- _ O
the -X- _ O
contribution -X- _ O
of -X- _ O
ERK1 -X- _ B-Intervention
/ -X- _ I-Intervention
2 -X- _ I-Intervention
in -X- _ O
early -X- _ O
steps -X- _ O
of -X- _ O
JUNV -X- _ B-Intervention
and -X- _ I-Intervention
TCRV -X- _ I-Intervention
multiplication. -X- _ I-Intervention
JUNV -X- _ B-Outcome
adsorption -X- _ I-Outcome
, -X- _ I-Outcome
internalization -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
uncoating -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
affected -X- _ I-Outcome
by -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
cultured -X- _ I-Outcome
cells -X- _ I-Outcome
with -X- _ I-Outcome
U0126 -X- _ I-Outcome
, -X- _ I-Outcome
an -X- _ I-Outcome
inhibitor -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
ERK1 -X- _ I-Outcome
/ -X- _ I-Outcome
2 -X- _ I-Outcome
signaling -X- _ I-Outcome
pathway. -X- _ I-Outcome
In -X- _ O
contrast -X- _ O
, -X- _ O
U0126 -X- _ B-Outcome
caused -X- _ I-Outcome
a -X- _ I-Outcome
marked -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
viral -X- _ I-Outcome
protein -X- _ I-Outcome
expression -X- _ I-Outcome
and -X- _ I-Outcome
RNA -X- _ I-Outcome
synthesis -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
JUNV -X- _ I-Outcome
RNA -X- _ I-Outcome
synthesis -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
augmented -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
presence -X- _ I-Outcome
of -X- _ I-Outcome
an -X- _ I-Outcome
activator -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
ERK1 -X- _ I-Outcome
/ -X- _ I-Outcome
2 -X- _ I-Outcome
pathway. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
U0126 -X- _ I-Outcome
impaired -X- _ I-Outcome
the -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
reporter -X- _ I-Outcome
gene -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
TCRV-based -X- _ I-Outcome
replicon -X- _ I-Outcome
system -X- _ I-Outcome
, -X- _ I-Outcome
confirming -X- _ I-Outcome
the -X- _ I-Outcome
ability -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
compound -X- _ I-Outcome
to -X- _ I-Outcome
hinder -X- _ I-Outcome
arenavirus -X- _ I-Outcome
macromolecular -X- _ I-Outcome
synthesis. -X- _ I-Outcome
By -X- _ I-Outcome
using -X- _ I-Outcome
a -X- _ I-Outcome
cell-based -X- _ I-Outcome
assay -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
determined -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
inhibitor -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
affect -X- _ I-Outcome
the -X- _ I-Outcome
translation -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
synthetic -X- _ I-Outcome
TCRV-like -X- _ I-Outcome
mRNA. -X- _ I-Outcome
No -X- _ I-Outcome
changes -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
pattern -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
translation -X- _ I-Outcome
factor -X- _ I-Outcome
eIF2α -X- _ I-Outcome
were -X- _ I-Outcome
found -X- _ I-Outcome
in -X- _ I-Outcome
U0126-treated -X- _ I-Outcome
cells. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
indicate -X- _ O
that -X- _ O
U0126 -X- _ B-Outcome
impairs -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
synthesis -X- _ I-Outcome
, -X- _ I-Outcome
thereby -X- _ I-Outcome
leading -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
subsequent -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
viral -X- _ I-Outcome
protein -X- _ I-Outcome
expression. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
we -X- _ O
conclude -X- _ O
that -X- _ O
ERK1 -X- _ B-Outcome
/ -X- _ I-Outcome
2 -X- _ I-Outcome
signaling -X- _ I-Outcome
activation -X- _ I-Outcome
is -X- _ I-Outcome
required -X- _ I-Outcome
for -X- _ O
an -X- _ O
efficient -X- _ O
arenavirus -X- _ O
RNA -X- _ O
synthesis -X- _ O
. -X- _ O

